ONPATTRO® (Patisiran) is a double-stranded small interfering ribonucleic acid targeted to hepatocytes for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
ONPATTRO® is manufactured by Almylam.
Administration and Dosage:
Onpattro is an intravenous infusion every 3 weeks.
Common Side Effects:
The more common side effects of ONPATTRO® include respiratory infections, such as colds, sinus infections, and nasal congestion, and infusion-related reactions.
Please read the full Prescribing Information for ONPATTRO® and discuss any questions you have with your doctor.
Ready to Schedule an Appointment?
Please CLICK HERE to get started.
ONPATTRO® is indicated to treat:
- Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis